SandozSandoz completes $170M buy of Lucentis biosimilar from Coherus BioSciences

04 Mar 2024
endpts.com
Drug ApprovalAcquisitionBiosimilar
Sandoz’s $170 million cash deal to buy ophthalmology biosimilar Cimerli from Coherus BioSciences has completed early following its announcement in January. The deal, which is the first for Sandoz since spinning off from Novartis, includes a biologics license application, product inventory and ophthalmology sales, according to Sandoz . Cimerli, a copycat version of Roche’s eye disease drug Lucentis, brought in $40 million in the third quarter of 2023, a 50% increase compared to the prior quarter, according to Coherus’ latest earnings report . The biosimilar, an anti-VEGF therapy, won approval in August 2022. It is the only approved ranibizumab biosimilar to Roche’s Lucentis injection covering the same five eye conditions: wet AMDAMD, diabetic retinopathy, diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.